康柏西普不同给药方案治疗视网膜中央静脉阻塞继发黄斑水肿的疗效对比  

Effect of Different Administration Regimens of Conbercept on Macular Edema Secondary to Central Retinal Vein Occlusion

作　　者：李成智 韦禹婵 LI Cheng-Zhi;WEI Yu-Chan(Yizhou District Hospital of Traditional Chinese Medicine,Hechi 546300,China)

机构地区：[1]河池市宜州区中医医院

出　　处：《中国药物经济学》2024年第12期84-87,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨康柏西普不同给药方案治疗视网膜中央静脉阻塞(CRVO)继发黄斑水肿(ME)的疗效。方法选取2022年7月至2023年7月河池市宜州区中医医院眼科收治的77例CRVO-ME患者为研究对象,按治疗方案不同分为5+PRN组(n=41)和3+PRN组(n=36)。5+PRN组1次/月、连续5个月玻璃体内注射康柏西普,随后按需治疗(PRN);3+PRN组1次/月、连续3个月玻璃体内注射康柏西普,随后PRN。比较两组玻璃体内注射次数、激光光凝补救治疗次数、最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)、眼压及不良反应。结果5+PRN组注射次数及激光光凝补救治疗次数为(2.13±1.08)次、(1.46±0.62)次,3+PRN组为(4.52±1.65)次、(1.91±0.74)次,组间比较差异显著(P<0.05)。治疗后1、3、6个月,两组BCVA均较治疗前显著改善(P<0.05),但两组BCVA比较无统计学差异(P>0.05)。治疗后1、3、6个月,两组CMT均较治疗前显著降低(P<0.05),但两组间CMT比较无统计学差异(P>0.05)。治疗前后,两组眼压比较无统计学差异(P>0.05)。两组不良反应发生率比较无统计学差异(P>0.05)。结论康柏西普5+PRN、3+PRN方案治疗CRVO-ME效果相似,但5+PRN方案仅需较少的PRN次数即可获得稳定的疗效。Objective To explore the effect of different administration regimens of conbercept on macular edema(ME secondary to central retinal vein occlusion(CRVO).Methods Seventy-seven patients with CRVO-ME admitted to the Ophthalmology department of Yizhou District Hospital of Traditional Chinese Medicine of Hechi City from July 2022 to July 2023were selected as the study objects,and were divided into 5+PRN group(n=41)and 3+PRN group(n=36)according to different treatment plans.In the 5+PRN group,intravitreal injection of conbercept was given once a month for 5 consecutive months,followed by pro re nata(PRN).In the 3+PRN group,intravitreal injection of conbercept was given once a month for 3 months,followed by PRN.The intravitreous injection times,laser photocoagulation treatment times,best corrected visual acuity(BCVA),macular foveal retinal thickness(CMT),intraocular pressure and adverse reactions were compared between two groups.Results The number of injection times and the number of laser photocoagulation remedial treatment times were(2.13±1.08)and(1.46±0.62)times in the 5+PRN group,and(4.52±1.65)and(1.91±0.74)times in the 3+PRN group,and there were significant differences between the groups(P<0.05).At 1,3 and 6 months after treatment,BCVA in both groups was significantly improved compared with that before treatment(P<0.05),but there was no significant difference in BCVA between the two groups(P>0.05).At 1,3 and 6 months after treatment,CMT in both groups was significantly decreased compared with that before treatment(P<0.05),but there was no significant difference in CMT between the two groups(P>0.05).Before and after treatment,there was no significant difference in IOP between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The effect of conbercept 5+PRN and 3+PRN regiments in the treatment of CRVO-ME is similar,while 5+PRN regiments require fewer PRN times to achieve stable efficacy.

关 键 词：康柏西普 视网膜中央静脉阻塞 黄斑水肿 按需治疗 

分 类 号：R774.5[医药卫生—眼科] R988.1[医药卫生—临床医学]